An endocrine system is a group of glands that create and release hormones to control important bodily functions, such as metabolism, growth, reproduction, etc. The endocrine system plays a vital role in the prevention of several chronic and metabolic diseases. Endocrine disorders are classified into two types: diseases caused by the glands overproducing or underproducing hormones (hormone imbalance) and diseases caused by the development of lesions in the endocrine system.
The purpose of this research study titled "Endocrine Testing Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" is to provide investors, developers, company executives, and industry participants with in-depth analysis to allow them to take strategic initiatives and decisions related to the prospects in the global endocrine testing market. This report presents and analyses the major trends prevalent in the global endocrine testing market and provides market size and forecast.
This report categorizes the global endocrine testing market in terms of test type, endocrine disorder, testing technology, end-users, and geographical distribution.
For the purpose of this study, the test types considered include estradiol (E2) testing, follicle-stimulating hormone (FSH) testing, human chorionic gonadotropin (hCG) hormone testing, luteinizing hormone (LH) testing, dehydroepiandrosterone sulfate (DHEAS) testing, progesterone testing, testosterone testing, stimulating thyroid hormone (TSH) testing, prolactin testing, cortisol testing, insulin testing, and others. The endocrine disorders studied in this report are categorized as adrenal disorders, calcium problems, glucose (islet cell) disorders, male and female gonadal problems, hypertensive and heart disorders, thyroid disorders, and pituitary disorders.
Based on testing technologies, the global endocrine testing market is studied for immunoassay technology, tandem mass spectrometry, sensor technology, monoclonal and polyclonal antibody technology, clinical chemistry technology, and others. This report also categorizes the global endocrine testing market by end-users such as hospitals, clinical laboratories, research and academia, and others. The market size and forecast for each mentioned segment for the period 2015–2025 are presented in the report, along with respective CAGRs for the forecast duration of 2017–2025.
Geographically, the global endocrine testing market is best understood by segmenting it into five major regions and five major region-level markets, which are as follows:
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Mexico
rest of Latin America
Middle East and Africa
GCC
Rest of the Middle East and Africa
The market size and forecast of each considered geographical market are presented for the period 2015-2025, along with CAGRs for the forecast period 2017-2025, and further cross-sectional analysis is presented in terms of test type, endocrine disorder, testing technology, end-users, and constituent region/country level markets.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global endocrine testing market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the endocrine testing market. The key players profiled in this report are Abbott Laboratories, AB Sciex Pte Ltd., Agilent Technologies, Inc., Biomedical Technologies (Alfa Aesar), bioMérieux SA, Bio-Rad Laboratories, Inc., DiaSorin, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Ortho-clinical Diagnostics, Quest Technology Pte Ltd., Sysmex Corporation, and Teleflex Incorporated.
Based on the types of disorders, the global endocrine testing market is segmented as follows:
Adrenal Disorders
Calcium Problems
Disorders of Glucose (Islet Cells)
Male and female gonadal problems
Heart Disorders
Hypertensive Disorders
Thyroid Disorders
Pituitary Disorders
Diabetes is among the most prominent areas where endocrine testing is widely used. As the global prevalence of diabetes rises, experts believe that there is still a large population of undiagnosed patients. People can have prediabetes or type 2 diabetes for several years without exhibiting distinguishable symptoms. As a matter of fact, type 2 diabetes often goes undiagnosed until the related complications appear. Such complications include renal disease, vision impairment, and even nerve damage. If not diagnosed in time and left untreated, diabetes can result in several complications and eventual mortality. Diabetes diagnosis is critical for making the necessary lifestyle changes or taking the necessary medications for disease management. Diabetes screening is frequently advised in people who are at high risk of developing diabetes.
For the purpose of this study, the global endocrine testing market is studied for the following test types:
Testing for Estradiol (E2)
FSH (Follicle Stimulating Hormone) Testing
Human Chorionic Gonadotropin (hCG) Hormone Testing
Testing for Luteinizing Hormone (LH)
Testing for Dehydroepiandrosterone Sulfate (DHEAS)
Progesterone Testing
Testosterone Testing
Thyroid-Stimulating Hormone (TSH) Testing
Prolactin Testing
Cortisol Testing
Insulin Testing
Others
Among the considered test types, thyroid stimulating hormone testing and insulin testing together will capture the largest market share throughout the forecast period of 2017–2025. Thyroid function disorders are common worldwide, and screening and diagnosis form a critical part of disease management. Symptoms of thyroid disorders are extremely prevalent in the general population and are non-specific. Increasing information available to the general public has led to voluntary testing by patients worldwide. TSH, T4, and anti-TPO antibodies are the three most important biochemical tests for assessing thyroid function. The TSH testing assay is the most reliable for detecting primary hypo- and hyperthyroidism, whereas first-generation TSH testing can only detect hypothyroidism.
For the purpose of this study, the global endocrine testing market is segmented as per the following technologies:
Immunoassay Technology
Tandem mass spectrometry
Sensors Technology
Monoclonal and polyclonal antibody technology
clinical chemistry technology
Others
The increasing prevalence of metabolic disorders, sexual dysfunction, diabetes, renal diseases, and obesity has resulted in an increase in demand for endocrine testing methods. Regular monitoring of endocrine hormones plays a critical role in the management of diabetes and related complications across all demographics. There is also an increasing significance of obesity as a co-morbidity in the growing prevalence of disorders of the reproductive system, strokes, cardiovascular diseases, and cancer.
This increase in the patient pool is expected to favor the growth of the endocrine testing market. However, the high costs of novel testing technologies may restrain the widespread acceptance of these tests, especially in developing countries. Among the currently available testing technologies, immunoassay technology is the largest revenue-generating segment, and it is anticipated that the trend will continue during the forecast period. Technologies such as tandem mass spectrometry will witness significant traction through the forecast period as a result of their proven precision and accuracy in result delivery.
Geographically, the global endocrine testing market is cumulative for North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America.
North America (U.S. and Canada) is the clear leader in the global endocrine testing market, followed by Europe. The significant prevalence of obesity, chronic endocrine disorders such as diabetes and thyroid diseases, and reproductive health disorders are the key factors contributing to the dominance of the North American market. Furthermore, supportive government regulations facilitating the swift adoption of novel testing technologies and an evolving reimbursement scenario will additionally drive the North American endocrine testing market. On the other hand, a huge population base and rising incidence of lifestyle-related diseases have led to the emergence of Asia Pacific as the fastest-growing regional market for endocrine testing.
The detailed regional classification of the global endocrine testing market is as follows:
North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, and the Rest of Europe)
Asia Pacific (China, Japan, and the Rest of Asia Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America)
Middle East and Africa (GCC plus the rest of the Middle East and Africa)
Frequently Asked Question:
The market for Endocrine Testing Market is expected to reach USD$ 14,758.6 Mn in 2025.
The Endocrine Testing Market is expected to see significant CAGR growth over the coming years, at 7.9%.
